1186 / 1708
Issues with Application of
Metastatic Site RT?
•
Currently
Persistently MIBG-Avid lesions post induction or residual soft tissue
disease
•
Future
➢
All neuroendocrine cells with active NE transporter
➢
Active NB with active NE transporter
➢
Persistently MIBG-Avid lesions post induction
➢
Residual soft tissue disease